Notably, both adoptive transfer of Nano ZSA-51D-reprogrammed neutrophils and systemic Nano ZSA-51D treatment synergizes with α-PD1 therapy to achieve complete remission of colon tumors through neutrophil- and CD8<sup>+</sup> T cell-dependent mechanisms, with potent efficacy also validated in otherwise immune-resistant pancreatic cancer models. The gene discussed is CD8A; the disease is pancreatic neoplasm.